This Substack is reader-supported. To receive new posts and support my work, consider becoming a free or paid subscriber.
The Event. The Q2 10-Q and business update landed this morning. Cash and equivalents: $9.8 million as of June 30, 2026, down from $21.6M at year-end. Net cash used in operations for the first six months: $13.4 million. And buried in Liquidity and Capital Resources is the sentence that matters more than any of it — the August 12 Securities Purchase Agreement and Warrant Inducement Letters carry a standstill barring Aptevo from using the First SEPA, the Second SEPA, or the ATM to raise capital until 12 months after the Stockholder Approval Date.
The Reaction. The stock has gone from $3.50 on Tuesday to $2.94 today, -16.0% in two sessions. That is not the market reading a mipletamig data table. That is the market reading a warrant schedule.
The Reality. Two days ago I called the $4.5M raise “a bridge to the next bridge.” The 10-Q reveals the toll on that bridge: to get $4.5M gross now, management contractually gave up access to the $66.8M of nominal equity-line capacity for a year. The refuel stop cost them the fuel depot.
The Receipts
Cash: $9.8M against a $6.4M quarterly operating loss. Q2 net loss was $6.36M; six-month net cash used in operations was $13.4M, or roughly $6.7M per quarter. The implication: on cash alone, that’s about a quarter and a half. The $4.5M gross from Monday buys perhaps seven more weeks before fees. Going-concern language is restated verbatim in Note 1 — substantial doubt for the one-year period from issuance.
The standstill is the new fact. Until 12 months after stockholder approval, Aptevo is prohibited from any variable-price equity financing — which is precisely what a SEPA and an ATM are. There’s also a shorter blackout on issuing any stock or filing any registration statement until three months after approval/effectiveness. Why it matters: in the deep dive I described the funding stack — $85M nominal Yorkville capacity, ~$67M remaining, plus the Roth ATM — as the thing keeping the lights on. That stack is now switched off by contract. The financing plan for the next twelve months is, in practice, warrant exercises and whatever a strategic partner might pay.
The warrant overhang is now enormous. As of August 13 there are 6,058,397 common warrants outstanding against 1,801,970 shares outstanding. The August tranches alone — 1,274,610 inducement warrants and 4,308,540 PIPE warrants, all struck at $4.03 — represent $22.5M of potential proceeds and roughly 3.1x the current share count in exercisable paper. The implication: this is the capital plan. Which means the company now needs the stock above $4.03 for its own financing to function — and the stock closed today at $2.94, 27% below that strike. Warrants struck out of the money raise nothing.
RAINIER slips a beat. Phase 1b completion and RP2D selection are still guided to this year, but the Phase 2 regulatory interaction is now specified as 1Q27. Why it matters: my catalyst calendar had “RAINIER Phase 1b completion / Phase 2 dose selection — 2H 2026” as the only near-term value-bearing readout. It still is. But a Phase 2 that starts after an FDA meeting in 1Q27 means the actual randomized, controlled data that could settle the efficacy argument is years away — and there’s a $2.0 million OMT milestone payment due upon dosing the first Phase 2 patient, which is a fifth of the current cash balance.
The efficacy numbers barely moved. The updated cut across 31 evaluable frontline patients: 87% clinical benefit, 81% remission, 55% MRD-negative among CR/CRi patients, 36% of remitters TP53-mutant, no CRS through Cohort 5, 6 patients bridged to allogeneic transplant. Prior cut: 87%/81%/52%/35%. The implication: this is the same dataset with a slightly refreshed coat of paint, not new information.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.